|Bid||20.51 x 1200|
|Ask||24.99 x 800|
|Day's Range||22.51 - 23.26|
|52 Week Range||6.25 - 23.26|
|Beta (5Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.96|
CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference being held virtually on Tuesday, December 1, 2020 at 2:15 p.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.CONTACT:Investors: Amicus Therapeutics Andrew Faughnan Director, Investor Relations firstname.lastname@example.org (609) 662-3809Media: Amicus Therapeutics Diana Moore Head of Global Corporate Communications email@example.com (609) 662-5079FOLD–G
The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.
Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD) will be pleased this week, given that the stock price is up...